Novartis Pays US$100 M Upfront for Legend Biotech’s CAR-T Cell Therapies

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)

Published: 29 Nov-2023

DOI: 10.3833/pdr.v2023.i11.2838     ISSN: 1756-7874

Section: Licensing



Novartis has signed a global licensing agreement with Legend Biotech to advance the latter’s chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including LB1102 for the treatment of extensive stage small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details